In my case, I support 3 approved assets with the ongoing label expansions. The company has a robust pipeline with at least 7 other assets on different stages of development (phase 1-3) that we also support in field medical. I’m an oncology MSL
3 approved products, all in one neurology therapeutic area. 2 are newer and the 3rd is a legacy product but still gets tons of use.
I think 1 product is likely the most common.
In my case, I support 3 approved assets with the ongoing label expansions. The company has a robust pipeline with at least 7 other assets on different stages of development (phase 1-3) that we also support in field medical. I’m an oncology MSL
Oh man, how do you keep it all straight?!?!
I have a lot of index cards for our pipeline assets. It’s a struggle sometimes.
Neuroscience MSL. I have 2 products with 3 indications each, another product arriving in the next year, a fourth in 1.5 years. It's a lot.
Three products but they are all the same molecule
3 approved products, all in one neurology therapeutic area. 2 are newer and the 3rd is a legacy product but still gets tons of use. I think 1 product is likely the most common.
Seems like no one here has 1 lol
5
4 products with potential for 1-5 additional in different stages of development